U.S. Markets closed
  • S&P Futures

    3,796.75
    +6.25 (+0.16%)
     
  • Dow Futures

    30,843.00
    +15.00 (+0.05%)
     
  • Nasdaq Futures

    13,042.75
    +57.25 (+0.44%)
     
  • Russell 2000 Futures

    2,143.30
    -4.00 (-0.19%)
     
  • Crude Oil

    53.25
    +0.27 (+0.51%)
     
  • Gold

    1,846.50
    +6.30 (+0.34%)
     
  • Silver

    25.48
    +0.16 (+0.61%)
     
  • EUR/USD

    1.2146
    +0.0013 (+0.1093%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3649
    +0.0015 (+0.1078%)
     
  • USD/JPY

    103.7680
    -0.1240 (-0.1194%)
     
  • BTC-USD

    35,894.25
    -340.98 (-0.94%)
     
  • CMC Crypto 200

    711.50
    -3.69 (-0.52%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,538.74
    -94.76 (-0.33%)
     

Adamas to Present at Upcoming H.C. Wainwright Conference

Adamas Pharmaceuticals, Inc.
·1 min read

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.

A replay of the pre-recorded fireside chat will be available beginning January 11, 2021 in the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replay will be available for 30 days.

About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com